Loading...
01/09 23:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture. Financials show a cash decrease, but the cash runway is secure until 2027. Product development updates are promising, with regulatory alignment and no barriers to Phase II trials. However, uncertainties remain, such as the Servier arbitration decision and lack of milestone payment details. The Q&A session did not reveal major negative sentiments but highlighted cautious optimism from management. The overall sentiment is neutral, as positive product development is offset by financial and legal uncertainties.
Cash, Cash Equivalents, and Fixed-Term Deposits $230 million as of June 30, 2025, compared to $264 million as of December 31, 2024, a decrease of $33.2 million. The decrease is mainly due to $13.4 million of cash inflow from revenue and $5.1 million of interest income, offset by cash payments to suppliers ($23.2 million), wages, bonuses, and social expenses ($23.6 million), lease debt payments ($5.4 million), and repayment of the PGE loan ($2.6 million).
UCART22 (lasme-cel): Completed Phase I trials for relapsed or refractory acute lymphoblastic leukemia. Preparing for pivotal Phase II trial in H2 2025. Additional trial sites being set up in the US, Europe, and UK.
UCART20x22 (eti-cel): Phase I trials ongoing for relapsed or refractory non-Hodgkin lymphoma. Data to be presented at ASH Annual Conference in Q4 2025. Transition to Phase II preparation expected in 2026.
Geographic Expansion: Expanding clinical trial sites in the US, Europe, and UK to accelerate recruitment for UCART22 and UCART20x22 trials.
Financial Position: Cash, cash equivalents, and fixed-term deposits as of June 30, 2025, amount to $230 million, sufficient to fund operations into H2 2027.
R&D Collaboration: Ongoing research and development under partnership with AstraZeneca, including three cell and gene therapy programs for hematological malignancies, solid tumors, and a genetic disorder.
Arbitration with Servier: Arbitral decision expected by December 15, 2025, regarding termination of agreement and compensation for losses due to halted CD19 product development.
Leadership Changes: André Muller appointed to Board of Directors. Gratitude expressed to outgoing directors Pierre Bastid and Axel-Sven Malkomes for their contributions.
Regulatory Challenges: The company faces regulatory challenges in advancing its clinical trials, including the need for productive interactions with the FDA and EMA to progress to Phase II trials. This could delay timelines or impact trial outcomes.
Arbitration with Servier: Cellectis is involved in an arbitration with Servier regarding the termination of a licensing agreement and compensation for losses. The outcome of this arbitration, expected by December 2025, could impact financials and strategic plans.
Financial Sustainability: While the company has sufficient cash to fund operations into H2 2027, there has been a $33.2 million decrease in cash reserves in the first half of 2025, which could pose risks if revenue generation does not improve.
Clinical Trial Recruitment: Challenges in recruiting patients for clinical trials, particularly for Phase II studies, could delay the development and approval of key product candidates.
Market Challenges in Biotech: The company acknowledges the challenges of the biotech market, which could impact funding, partnerships, and overall business operations.
Initiation of pivotal Phase II trial for lasme-cel (UCART22): Cellectis plans to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025. Additional trial sites are being set up in the United States, Europe, and the United Kingdom to accelerate recruitment.
NatHaLi-01 study progress: Cellectis anticipates presenting Phase I data and outlining the late-stage development strategy for the NatHaLi-01 study (UCART20x22) in relapsed or refractory non-Hodgkin lymphoma by late 2025. Transition to Phase II preparation is expected in 2026.
R&D Day announcement: Cellectis will host an Investors R&D Day on October 16, 2025, to present Phase I data and late-stage development strategy for lasme-cel (UCART22) and share insights on the company's vision and capabilities.
ASH Annual Conference submissions: Phase I data from both the BALLI-01 (UCART22) and NatHaLi-01 (UCART20x22) studies have been submitted for presentation at the ASH Annual Conference in Q4 2025.
AstraZeneca partnership: Research and development activities are ongoing under the partnership with AstraZeneca, focusing on three programs: one allogeneic CAR-T for hematological malignancies, one allogeneic CAR-T for solid tumors, and one in vivo gene therapy for a genetic disorder.
Arbitration with Servier: The arbitral decision regarding the dispute with Servier is expected to be rendered on or before December 15, 2025.
Financial outlook: Cellectis' cash, cash equivalents, and fixed-term deposits as of June 30, 2025, are sufficient to fund operations into the second half of 2027.
The selected topic was not discussed during the call.
The earnings call summary presents a mixed picture. Financials show a cash decrease, but the cash runway is secure until 2027. Product development updates are promising, with regulatory alignment and no barriers to Phase II trials. However, uncertainties remain, such as the Servier arbitration decision and lack of milestone payment details. The Q&A session did not reveal major negative sentiments but highlighted cautious optimism from management. The overall sentiment is neutral, as positive product development is offset by financial and legal uncertainties.
The earnings call reveals a strong financial position with significant investments from AstraZeneca and stable cash reserves. The Q&A section highlights confidence in upcoming data releases, suggesting positive future developments. The collaboration with AstraZeneca is fully reimbursed, reducing cash burn. Despite competitive pressures and supply chain challenges, the overall sentiment leans positive due to strategic partnerships and financial strength.
The earnings call presents mixed signals. The AstraZeneca collaboration and strong cash position are positive indicators, but supply chain challenges and intense competition in cell and gene therapy pose risks. The Q&A reveals management's cautious approach to prioritizing projects and lack of clarity on future datasets. Additionally, deprioritizing UCART123 raises concerns. Despite these issues, the partnership with AstraZeneca provides a financial buffer, mitigating some negative impacts. Overall, the sentiment is neutral as positives balance out the negatives.
The earnings call reveals strong financial improvement, with a significant turnaround from a loss to a profit, which is a positive indicator. The collaboration with AstraZeneca and the potential for new programs provide further optimism. The Q&A section highlights ongoing developments and market expansion potential, especially in the EU. Although management avoided some specifics, the overall sentiment remains positive due to the financial recovery and strategic partnerships.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
